Byetta
Jump to navigation
Jump to search
Byetta is an in injectable drug (exenatide) for the treatment of type 2 diabetes which is marketed by Amylin Pharmaceuticals and Eli Lilly. The drug was approved for use by the U.S. Food and Drug Administration for use in April 2005. [1]
Company Website
Website: http://www.byetta.com/index.jsp
Other SourceWatch Resources
External links
- U.S. Food and Drug Administration, "Patient Information Sheet: Exenatide (marketed as Byetta)", May 27, 2005.
- Marc Longpre, "Diabetes campaign urges active lifestyle", PR Week, March 20, 2007.
| This article is a stub. You can help by expanding it. |
